**PHARMACOLOGY FINAL 2025 (spring semester 6)**

***Nota Bene***!

* 1. All lecture notes &didactic materials You can find on:

<https://farmacologie.usmf.md/en/node/14228/pharmacology/didactic-materials>

* 1. PHARMACOLOGY BOOK:

<https://farmacologie.usmf.md/sites/default/files/inline-files/Pharmacology%20Book_0.pdf>

1. **Select the centrally acting non-opioid antitussive drug(s).**
2. **Select the antitussive agent(s) from the class of H1-antihistamines.**
3. **Select the centrally acting opioid antitussive drug(s) used in whooping cough (pertussis).**
4. **Select the centrally acting non-opioid antitussive drug(s) used in whooping cough (pertussis).**
5. **Select the class(es) of direct or mixed-acting secretostimulant expectorants.**
6. **Select the secretolytic expectorant(s) that primarily reduce sputum viscosity.**
7. **Select the secretolytic expectorant(s) used in cystic fibrosis.**
8. **Select the secretolytic expectorant(s) used in paracetamol poisoning.**
9. **Select the mechanism(s) of action of dornase alfa.**
10. **Select the mechanism(s) of action of acetylcysteine.**
11. Select the effect(s) of acetylcysteine.
12. Select the mechanism(s) of action of bromhexine.
13. Select the bronchodilator drug class(es) used in obstructive airway diseases.
14. Select the long-acting beta-2 adrenomimetic bronchodilator(s).
15. Select the ultra-long-acting beta-2 adrenomimetic bronchodilator(s).
16. Select the bronchodilatory effect(s) of beta-2 adrenomimetics.
17. Select the beta-2 adrenomimetic(s) used in acute bronchial asthma attacks.
18. Select the adverse reaction(s) of beta-2 adrenomimetics used as bronchodilators.
19. Select the short-acting selective muscarinic antagonist(s) used as bronchodilators.
20. Select the ultra-long-acting selective muscarinic antagonist(s) used as bronchodilators.
21. Select the bronchodilatory effect(s) of muscarinic antagonists.
22. Select the indication(s) for the use of muscarinic antagonists as bronchodilators.
23. Select the drug class(es) with anti-inflammatory, antiallergic, and bronchodilatory activity in obstructive airway diseases.
24. Select the antileukotriene agent(s) used in obstructive airway diseases.
25. Select the inhaled glucocorticoid(s) used in obstructive airway diseases.
26. Select the effect(s) of glucocorticoids used in obstructive airway diseases.
27. Select the indication(s) for the use of inhaled glucocorticoids in obstructive airway diseases.
28. Select the adverse reaction(s) of inhaled glucocorticoids.
29. Select the methylxanthine(s) used in obstructive airway diseases.
30. Select the mechanism(s) of action of methylxanthines in obstructive airway diseases.
31. Select the mechanism of action of doxofylline in obstructive airway diseases.
32. Select the effect(s) of methylxanthines in obstructive airway diseases.
33. Select the indication(s) for the use of methylxanthines in obstructive airway diseases.
34. Select the adverse reaction(s) of methylxanthines used in obstructive airway diseases.
35. Select the drug(s) used in status asthmaticus.
36. Select the antiarrhythmic effect(s) of Class 1A membrane-stabilizing agents.
37. Select the antiarrhythmic effect(s) of Class 1B membrane-stabilizing agents.
38. Select the antiarrhythmic effect(s) of Class 1C membrane-stabilizing agents.
39. Select the antiarrhythmic effect(s) of beta-adrenergic blockers.
40. Select the antiarrhythmic effect(s) of calcium channel blockers.
41. Select the antiarrhythmic effect(s) of amiodarone.
42. Select the pharmacokinetic properties of amiodarone.
43. Select the indication(s) for the use of lidocaine.
44. Select the indication(s) for the use of beta-adrenergic blockers as antiarrhythmic agents.
45. Select the antiarrhythmic mechanism of action of amiodarone.
46. Select the indication(s) for the use of amiodarone as an antiarrhythmic agent.
47. Select the adverse reaction(s) of amiodarone.
48. Select the indication(s) for the use of potassium and magnesium preparations.
49. Select the first-line antianginal drug(s) that reduce myocardial oxygen demand.
50. Select the second-line antianginal drug(s) that reduce myocardial oxygen demand.
51. **Select the systemic mechanism(s) of action of nitrates.**
52. **Select the indication(s) for the use of nitrates.**
53. **Select the indication(s) for the use of molsidomine.**
54. **Select the adverse reaction(s) of nitrates.**
55. **Select the antianginal effect(s) of beta-adrenergic blockers.**
56. **Select the antianginal effect(s) of calcium channel blockers.**
57. **Select the drug(s) used for relieving angina pectoris attacks.**
58. **Select the drug class(es) used in acute myocardial infarction.**
59. **Select the short-acting diuretic(s).**
60. **Select the intermediate-acting diuretic(s).**
61. **Select the long-acting diuretic(s).**
62. **Select the diuretic(s) acting at the collecting tubule.**
63. **Select the diuretic(s) acting at the cortical segment of the loop of Henle and distal tubule.**
64. **Select the indication(s) for the use of osmotic diuretics.**
65. **Select the adverse reaction(s) of osmotic diuretics.**
66. **Select the effect(s) of loop diuretics.**
67. **Select the indication(s) for the use of loop diuretics.**
68. **Select the adverse reaction(s) of loop diuretics.**
69. **Select the effect(s) of thiazide and thiazide-like diuretics.**
70. **Select the indication(s) for the use of thiazide and thiazide-like diuretics.**
71. **Select the adverse reaction(s) of thiazide and thiazide-like diuretics.**
72. **Select the effect(s) of aldosterone antagonist diuretics.**
73. **Select the indication(s) for the use of aldosterone antagonist diuretics.**
74. **Select the adverse reaction(s) of aldosterone antagonist diuretics.**
75. **Select the class(es) of colloidal plasma substitutes.**
76. **Select the effect(s) of dextrans.**
77. **Select the indication(s) for the use of dextrans.**
78. **Select the adverse reaction(s) of dextrans.**
79. **Select the drug(s) used in acute gout attacks.**
80. **Select the drug(s) used in the treatment of gout.**
81. **Select the drug(s) used in acidosis.**
82. **Select the specific characteristics of pancreatic enzymes in microcapsule form.**
83. **Select the indication(s) for the use of pancreatic enzyme preparations.**
84. **Select the class(es) of gastric antisecretory drugs.**
85. **Select the antisecretory drug(s) used in reflux esophagitis.**
86. **Select the adverse reaction(s) of H2-histamine receptor blockers.**
87. **Select the indication(s) for the use of prostaglandin analogs as antiulcer agents.**
88. **Select the indication(s) for the use of proton pump inhibitors.**
89. **Select the adverse reaction(s) of proton pump inhibitors.**
90. **Select the gastroprotective drug(s) used in gastric and duodenal ulcers.**
91. **Select the systemic antacid effect(s).**
92. **Select the effect(s) of non-absorbable antacids.**
93. **Select the adverse reaction(s) of systemic antacids.**
94. **Select the class(es) of prokinetic drugs.**
95. **Select the effect(s) of prokinetic drugs.**
96. **Select the indication(s) for the use of prokinetic drugs.**
97. **Select the class(es) of antiflatulent drugs.**
98. **Select the mechanism(s) of action of activated charcoal as an antiflatulent.**
99. **Select the mechanism(s) of action of plant-based carminatives as antiflatulents.**
100. **Select the mechanism(s) of action of bulk-forming laxatives.**
101. Select the indication(s) for the use of bulk-forming laxatives.
102. Select the stool-softening laxative(s).
103. Select the mechanism(s) of action of stool-softening laxatives.
104. Select the indication(s) for the use of stool-softening laxatives.
105. Select the osmotic purgative(s).
106. Select the mechanism(s) of action of osmotic purgatives.
107. Select the indication(s) for the use of osmotic purgatives.
108. Select the indication(s) for the use of the osmotic purgative macrogol.
109. Select the onset time of laxative effect for bulk-forming laxatives.
110. Select the onset time of laxative effect for emollient and lubricant laxatives.
111. Select the onset time of laxative effect for osmotic purgatives.
112. Select the onset time of purgative effect for bulk-forming purgatives.
113. Select the onset time of action for irritant purgatives acting on the small intestine.
114. Select the onset time of action for irritant purgatives acting on the large intestine.
115. Select the irritant purgative(s) acting on the small intestine.
116. Select the mechanism(s) of action of irritant purgatives acting on the small intestine.
117. Select the mechanism(s) of action of irritant purgatives acting on the large intestine.
118. Select the indication(s) for the use of irritant purgatives acting on the small intestine.
119. Select the indication(s) for the use of irritant purgatives acting on the large intestine.
120. Select the mixed-acting spasmolytic drug(s).
121. Select the mechanism(s) of action of myotropic spasmolytics.
122. Select the indication(s) for the use of neurotropic, myotropic, and mixed spasmolytics.
123. Select the antiemetic drug(s) used for medication-induced vomiting.
124. Select the antiemetic drug(s) used for chemotherapy-induced vomiting.
125. Select the antiemetic drug(s) used for motion sickness.
126. Select the class(es) of symptomatic and pathogenetic antidiarrheal agents.
127. Select the class(es) of antidiarrheal drugs used in nonspecific diarrhea.
128. Select the mechanism(s) of action of opioids as antidiarrheal agents.
129. Select the effect(s) of opioids as antidiarrheal agents.
130. Select the class(es) of hepatoprotective agents by origin.
131. Select the mechanism(s) of action of hepatoprotective agents.
132. Select the effect(s) of silymarin.
133. Select the effect(s) of ademetionine.
134. Select the effect(s) of ursodeoxycholic acid.
135. Select the class(es) of choleretic agents.
136. Select the mechanism(s) of action of bile acid preparations as choleretics.
137. Select the indication(s) for the use of bile acid preparations as choleretics.
138. Select the class(es) of cholecystokinetic agents.
139. Select the class(es) of cholespasmolytic agents.
140. Select the class(es) of positive inotropic drugs.
141. Select the class(es) of vasodilators used in heart failure.
142. Select the short-acting cardiac glycoside(s).
143. Select the medium-acting cardiac glycoside.
144. Select the cardiac glycoside with high liposolubility.
145. Select the water-soluble cardiac glycoside(s).
146. Select the cardiotonic mechanism of action of cardiac glycosides.
147. Select the effect(s) of cardiac glycosides on the heart.
148. Select the indication(s) for the use of cardiac glycosides.
149. Select the drug(s) used in the treatment of cardiac glycoside intoxication.
150. Select the pharmacokinetic properties of digoxin.
151. **Select the pharmacokinetic properties of strophanthin.**
152. **Select the ECG changes associated with the positive inotropic action of cardiac glycosides.**
153. **Select the ECG change(s) associated with the negative chronotropic action of cardiac glycosides.**
154. **Select the ECG change(s) associated with the negative dromotropic action of cardiac glycosides.**
155. **Select the class(es) of peripherally acting neurotropic antihypertensive drugs.**
156. **Select the class(es) of myotropic antihypertensive drugs.**
157. **Select the antihypertensive drug(s) that act on the renin–angiotensin–aldosterone system.**
158. **Select the mechanism of action of methyldopa.**
159. **Select the adverse reaction(s) of clonidine.**
160. **Select the mechanism of action of moxonidine.**
161. **Select the antihypertensive mechanism(s) of action of beta-adrenergic blockers.**
162. **Select the adverse reaction(s) of beta-adrenergic blockers as antihypertensive agents.**
163. **Select the antihypertensive effect(s) of calcium channel blockers.**
164. **Select the circulatory adverse effect(s) of calcium channel blockers.**
165. **Select the antihypertensive effect(s) of angiotensin-converting enzyme (ACE) inhibitors.**
166. **Select the adverse reaction(s) of ACE inhibitors used as antihypertensives.**
167. **Select the antihypertensive effect(s) of angiotensin receptor blockers.**
168. **Select the adverse reaction(s) of angiotensin receptor blockers used as antihypertensives.**
169. **Select the drug(s) used in hypertensive crises.**
170. **Select the drug(s) used in hypertensive emergencies.**
171. **Select the class(es) of peripherally acting vasoconstrictors used as antihypotensive agents.**
172. **Select the class(es) of antihypotensive agents that increase cardiac output.**
173. **Select the antihypotensive effect(s) of alpha-adrenergic agonists.**
174. **Select the antihypotensive effect(s) of alpha-beta adrenergic agonists.**
175. **Select the antihypotensive effect(s) of dopaminergic agonists.**
176. **Select the mechanism of action of thiourea derivatives used as antihypotensive agents.**
177. **Select the indication(s) for the use of thiourea derivatives as antihypotensive agents.**
178. **Select the antihypotensive effect(s) of beta-1 adrenergic agonists.**
179. **Select the class(es) of myotropic cerebral vasodilators.**
180. **Select the class(es) of neurotropic cerebral vasodilators.**
181. **Select the drug(s) used in acute migraine attacks.**
182. **Select the drug class(es) used in migraine prophylaxis.**
183. **Select the mechanism of action of triptans (indole derivatives) used as antimigraine agents.**
184. **Select the mechanism of action of thiourea derivatives used as antimigraine agents.**

**Antimicrobial & Antiparasitic medicines**

1. **Select the antibiotic(s) that inhibit bacterial cell wall synthesis.**
2. **Select the antibiotic(s) that inhibit bacterial protein synthesis.**
3. **Select the antibiotic that inhibits nucleic acid synthesis.**
4. **Select the antibiotic that disrupts cytoplasmic membrane permeability.**
5. **Select the antibiotic(s) with predominant activity against Gram-positive bacteria.**
6. **Select the antibiotic(s) with predominant activity against Gram-negative bacteria.**
7. **Select the broad-spectrum antibiotic(s).**
8. **Select the ultra-broad-spectrum antibiotic(s).**
9. **Select the antibiotic with an absolute bactericidal effect on microbes.**
10. **Select the antibiotic(s) with a degenerative bactericidal effect on microbes.**
11. **Select the antibiotic(s) with a bacteriostatic effect on microbes.**
12. **Select the mechanism responsible for the absolute bactericidal effect of antibiotics.**
13. **Select the mechanism responsible for the degenerative bactericidal effect of antibiotics.**
14. **Select the mechanism responsible for the bacteriostatic effect of antibiotics.**
15. **Select the characteristic adverse reaction(s) of penicillins.**
16. **Select the second-generation cephalosporin(s) for oral administration.**
17. **Select the second-generation cephalosporin(s) for parenteral administration.**
18. **Select the third-generation cephalosporin(s) for oral administration.**
19. **Select the third-generation cephalosporin(s) for parenteral administration.**
20. **Select the fourth-generation cephalosporin(s).**
21. **Select the fifth-generation cephalosporin(s).**
22. **Select the characteristic adverse reaction(s) of cephalosporins.**
23. **Select the antimicrobial spectrum of aminoglycosides.**
24. **Select the second-generation aminoglycoside(s).**
25. **Select the third-generation aminoglycoside(s).**
26. **Select the adverse reaction(s) of aminoglycosides.**
27. **Select the antimicrobial spectrum of macrolides.**
28. **Select the macrolide(s).**
29. **Select the lincosamide(s).**
30. **Select the characteristic adverse reaction of lincosamides.**
31. **Select the antimicrobial spectrum of tetracyclines.**
32. **Select the characteristic adverse reaction(s) of tetracyclines.**
33. **Select the adverse reaction(s) of amphenicol derivative antibiotics.**
34. **Select the antimicrobial spectrum of glycopeptide antibiotics.**
35. **Select the adverse reaction(s) of glycopeptide antibiotics.**
36. **Select the mechanism of action of polymyxins.**
37. **Select the adverse reaction(s) of polymyxins.**
38. **Select the antimicrobial spectrum of ansamycins.**
39. **Select the mechanism of action of ansamycins.**
40. **Select the specific indication(s) for the use of ansamycins.**
41. **Select the characteristic adverse reaction(s) of ansamycins.**
42. **Select the biochemical mechanism(s) of antimicrobial resistance.**
43. **Select the strategies for combating antimicrobial resistance.**
44. **Select the mechanism(s) of action of antiseptics.**
45. **Select the effect(s) of oxidizing antiseptics.**
46. **Select the effect(s) of anionic detergent antiseptics.**
47. **Select the effect(s) of cationic detergent antiseptics.**
48. **Select the antiseptic mechanism of action of chlorhexidine.**
49. **Select the antiseptic effect(s) of iodine preparations.**
50. **Select the mechanism(s) of action of hydrogen peroxide.**
51. **Select the mechanism(s) of action of potassium permanganate.**
52. **Select the mechanism of action of cationic detergents.**
53. **Select the mechanism(s) of action of alcohols.**
54. **Select the class(es) of antiseptics used for cavity irrigation in surgery.**
55. **Select the class(es) of antiseptics used in halitosis.**
56. **Select the combined systemic sulfonamide(s).**
57. **Select the components of combined systemic sulfonamides.**
58. **Select the components of azo compounds.**
59. **Select the antimicrobial spectrum of sulfonamides.**
60. **Select the mechanism(s) of action of combined systemic sulfonamides.**
61. **Select the characteristic adverse reaction(s) of sulfonamides.**
62. **Select the systemic-acting nitrofuran derivative(s).**
63. **Select the intestinal-acting nitrofuran derivative.**
64. **Select the antimicrobial spectrum of non-fluorinated quinolones.**
65. **Select the antimicrobial spectrum of fluoroquinolones.**
66. **Select the fluoroquinolone(s) used in tuberculosis treatment.**
67. **Select the mechanism(s) of action of fluoroquinolones.**
68. **Select the characteristic adverse reaction(s) of fluoroquinolones.**
69. **Select the nitroimidazole derivative(s).**
70. **Select the antimicrobial spectrum of nitroimidazole derivatives.**
71. **Select the mechanism(s) of action of nitroimidazole derivatives.**
72. **Select the indication(s) for the use of nitroimidazole derivatives.**
73. **Select the adverse reaction(s) of nitroimidazole derivatives.**
74. **Select the oxazolidinedione derivative(s).**
75. **Select the antimicrobial spectrum of oxazolidinediones.**
76. **Select the mechanism of action of oxazolidinediones.**
77. **Select the indication(s) for the use of oxazolidinediones.**
78. **Select the systemic-acting 8-hydroxyquinoline derivative.**
79. **Select the antimicrobial spectrum of systemic 8-hydroxyquinoline derivatives.**
80. **Select the mechanism of action of systemic 8-hydroxyquinoline derivatives.**
81. **According to WHO, Select the first-line antituberculosis drug(s) used in drug-sensitive tuberculosis.**
82. **According to WHO, Select the antituberculosis drug(s) used in the treatment of drug-resistant tuberculosis (Group A).**
83. **According to WHO, Select the antituberculosis drug(s) used in the treatment of drug-resistant tuberculosis (Group B).**
84. **Select the antituberculosis drug(s) that inhibit cell wall synthesis.**
85. **Select the antituberculosis drug(s) that inhibit protein synthesis.**
86. **Select the antituberculosis drug(s) that inhibit nucleic acid synthesis.**
87. **Select the antituberculosis drug(s) that inhibit energy metabolism.**
88. **Select the adverse reaction(s) of isoniazid.**
89. **Select the adverse reaction(s) of ethambutol.**
90. **Select the adverse reaction(s) of pyrazinamide.**
91. **Select the first-line antileprosy drug(s).**
92. **Select the mechanism(s) of action of antileprosy drugs.**
93. **Select the rapidly acting hematoschizotropic drug(s) used in malaria.**
94. **Select the tissue schizotropic drug(s) used in malaria.**
95. **Select the gametocytocidal drug(s) used in malaria.**
96. **Select the mechanism(s) of action of antimalarial drugs.**
97. **Select the antimalarial drug(s) used in acute malaria attacks.**
98. **Select the drug(s) used in amebiasis of any localization.**
99. **Select the class(es) of drugs used in intestinal and intestinal wall-localized amebiasis.**
100. **Select the drug(s) used in trichomoniasis.**
101. **Select the drug(s) used in giardiasis.**
102. **Select the drug(s) used in toxoplasmosis.**
103. **Select the mechanism(s) of action of drugs used in toxoplasmosis.**
104. **Select the drug(s) used in pneumocystosis.**
105. **Select the mechanism(s) of action of drugs used in pneumocystosis.**
106. **Select the drug(s) used in intestinal nematode infections.**
107. **Select the mechanism(s) of action of drugs used in intestinal nematode infections.**
108. **Select the drug(s) used in intestinal cestode infections.**
109. **Select the mechanism(s) of action of drugs used in intestinal cestode infections.**
110. **Select the drug(s) used in extraintestinal helminth infections.**
111. **Select the mechanism(s) of action of drugs used in extraintestinal helminth infections.**
112. **Select the drug(s) used in the treatment of syphilis.**
113. **Select the anti-influenza antiviral drug(s).**
114. **Select the mechanism(s) of action of anti-influenza drugs.**
115. **Select the indication(s) for the use of anti-influenza drugs.**
116. **Select the antiherpetic antiviral drug(s).**
117. **Select the mechanism(s) of action of antiherpetic drugs.**
118. **Select the antiretroviral antiviral drug(s).**
119. **Select the mechanism(s) of action of antiretroviral drugs.**
120. **Select the adverse reaction(s) of antiretroviral drugs.**
121. **Select the antiviral drug(s) used in viral hepatitis B.**
122. **Select the mechanism of action of interferon.**
123. **Select the early adverse reaction(s) of interferon preparations.**
124. **Select the antiviral drug(s) used in viral hepatitis C.**
125. **Select the antiviral drug(s) used in papillomavirus infections.**
126. **Select the antiviral drug(s) used in cytomegalovirus infections.**
127. **Select the drug(s) used in SARS-CoV-2 or COVID-19 infection.**
128. **Select the antifungal antibiotic(s).**
129. **Select the imidazole derivative(s) used as antifungal agents.**
130. **Select the triazole derivative(s) used as antifungal agents.**
131. **Select the echinocandin derivative(s) used as antifungal agents.**
132. **Select the mechanism of action of antifungal antibiotics.**
133. **Select the adverse reaction(s) of amphotericin B.**
134. **Select the mechanism of action of imidazole and triazole derivatives.**
135. **Select the adverse reaction(s) of triazole derivatives.**
136. **Select the mechanism of action of echinocandins.**

**Antiallergic Drugs**

1. **Select the class of antiallergic drugs that act as competitive mediator antagonists.**
2. **Select the class(es) of antiallergic drugs that act as functional mediator antagonists.**
3. **Select the antiallergic drug(s) used in anaphylactic shock.**
4. **Select the antiallergic drug(s) used in bronchial asthma attacks.**
5. **Select the second-generation H1-antihistamines.**
6. **Select the third-generation H1-antihistamines.**
7. **Select the effect(s) of H1-antihistamines.**
8. **Select the indication(s) for the use of H1-antihistamines.**
9. **Select the adverse reaction(s) of H1-antihistamines.**
10. **Select the effect(s) of epinephrine in anaphylactic shock.**

**Hormonal Drugs**

1. **Select the mechanism(s) of action of peptide-structured hormonal preparations.**
2. **Select the mechanism(s) of action of steroid-structured hormonal preparations.**
3. **Select the hypothalamic hormonal preparation(s).**
4. **Select the adenohypophyseal hormonal preparation(s).**
5. **Select the mechanism(s) of action of thyroid hormone preparations.**
6. **Select the effect(s) of thyroid hormone preparations.**
7. **Select the indication(s) for the use of thyroid hormone preparations.**
8. **Select the pharmacokinetic properties of levothyroxine.**
9. **Select the antithyroid drug(s).**
10. **Select the indication(s) for the use of thioamide antithyroid drugs.**
11. **Select the indication(s) for the use of iodine preparations as antithyroid agents.**
12. **Select the adverse reaction(s) of thioamide antithyroid drugs.**
13. **Select the pharmacokinetic properties of thiamazole.**
14. **Select the antithyroid mechanism of beta-adrenergic blockers.**
15. **Select the mechanism(s) of action of iodine preparations as antithyroid agents.**
16. **Select the oral antidiabetic drug from the biguanide class.**
17. **Select the oral antidiabetic drug(s) from the sulfonylurea class.**
18. **Select the oral antidiabetic drug(s) from the DPP-4 inhibitor class.**
19. **Select the antidiabetic drug(s) from the meglitinide class.**
20. **Select the oral antidiabetic drug(s) from the GLP-1 agonist class.**
21. **Select the oral antidiabetic drug(s) from the sodium-glucose cotransporter-2 (SGLT2) inhibitor class.**
22. **Select the oral antidiabetic drug class(es) that stimulate insulin release.**
23. **Select the oral antidiabetic drug class(es) that increase insulin sensitivity.**
24. **Select the oral antidiabetic drug class(es) that inhibit carbohydrate absorption.**
25. **Select the oral antidiabetic drug class(es) that enhance glucose utilization.**
26. **Select the ultra-rapid and ultra-short-acting human insulin preparation(s).**
27. **Select the long-acting insulin analog(s).**
28. **Select the ultra-long-acting insulin analog.**
29. **Select the effect(s) of insulin preparations on lipid metabolism.**
30. **Select the effect(s) of insulin preparations on carbohydrate metabolism.**
31. **Select the mechanism(s) of action of insulin preparations.**
32. **Select the adverse reaction(s) of insulin preparations.**
33. **Select the manifestations of hypoglycemia induced by insulin preparations.**
34. **Select the absolute indication(s) for the use of insulin preparations.**
35. **Select the insulin preparation(s) used in diabetic coma.**
36. **Select the drug(s) used in hypoglycemic coma.**
37. **Select the mechanism(s) of action of biguanides.**
38. **Select the effect(s) of biguanides.**
39. **Select the indication(s) for the use of biguanides.**
40. **Select the mechanism(s) of action of sulfonylureas.**
41. **Select the mechanism(s) of action of DPP-4 inhibitors.**
42. **Select the mechanism(s) of action of GLP-1 receptor agonists.**
43. **Select the mechanism of action of tetrasaccharides.**
44. **Select the mechanism of action of meglitinides.**
45. **Select the mechanism(s) of action of thiazolidinediones.**
46. **Select the mechanism of action of sodium-glucose cotransporter-2 (SGLT2) inhibitors.**
47. **Select the glucocorticoid(s) used for topical administration.**
48. **Select the glucocorticoid(s) used for intravenous administration.**
49. **Select the glucocorticoid(s) used for intramuscular administration.**
50. **Select the genomic mechanism of action of glucocorticoids.**
51. **Select the non-genomic mechanism(s) of action of glucocorticoids.**
52. **Select the glucocorticoid(s) with the strongest non-genomic mechanism of action.**
53. **Select the antiallergic properties of glucocorticoids.**
54. **Select the anti-inflammatory properties of glucocorticoids.**
55. **Select the anti-shock properties of glucocorticoids.**
56. **Select the effect(s) of glucocorticoids on fluid and electrolyte metabolism.**
57. **Select the effect(s) of glucocorticoids on lipid metabolism.**
58. **Select the effect(s) of glucocorticoids on protein metabolism.**
59. **Select the effect(s) of glucocorticoids on carbohydrate metabolism.**
60. **Select the pharmacodynamic indication(s) for the use of glucocorticoids.**
61. **Select the adverse reaction(s) of glucocorticoids.**
62. **Select the synthetic non-steroidal estrogen preparation(s).**
63. **Select the specific effect(s) of estrogen preparations.**
64. **Select the indication(s) for the use of estrogen preparations for hormone replacement therapy.**
65. **Select the semi-synthetic progestin(s) that are testosterone analogs.**
66. **Select the specific effect(s) of progestin preparations.**
67. **Select the semi-synthetic androgen preparation(s).**
68. **Select the specific effect(s) of androgen preparations.**
69. **Select the antiandrogen drug(s).**
70. **Select the antiestrogen drug(s).**